FDA Fast Track Designation Broadens Zymeworks’ ZW191 Potential for Ovarian Cancer—What’s Behind the Move?
Market Chameleon (Mon, 30-Mar 7:53 AM)
Zymeworks Highlights Promising Zanidatamab Data Across HER2+ Cancers at Upcoming AACR Meeting
Market Chameleon (Wed, 18-Mar 7:53 AM)
